Revier Therapeutics launches with €6M seed to target cardiometabolic disease
What's the deal? Heidelberg-based Revier TherapeuticsDealroom has a profile for this one. Try Dealroom → has launched with a €6 million seed round to develop disease-modifying therapies for cardiometabolic disease. KHAN Technology Transfer Fund II led the round, with participation from High-Tech Gründerfonds, VORNvcDealroom has a profile for this one. Try Dealroom →, and private investors through Revier Invest HeidelbergDealroom has a profile for this one. Try Dealroom →.
What's the endgame? The company has built the first therapeutic approach that selectively targets class IIa histone deacetylases (HDACs) for cardiometabolic diseases. Its orally available small molecules are designed to inhibit the disease-driving enzymatic activity while preserving healthy biological function.
Why now? Revier is starting with two indications: heart failure with preserved ejection fraction (HFpEF) and atherosclerotic cardiovascular disease (ASCVD). Chief executive officer Eva van Rooij said millions of these patients "still to date face limited targeted treatment options."
Earlier HDAC inhibitors targeted multiple classes at once, causing dose-limiting side effects. Scientific founder Johannes Backs said Revier's compounds "selectively target class IIa HDACs," a mode of action "designed to be therapeutically effective while maintaining a beneficial safety profile."
Where does the money go? Revier will fund its preclinical pipeline, led by the HFpEF programme and followed by ASCVD, plus the build-out of its operational, scientific, and clinical functions.
The signal: Investors are betting that precision within an established but troubled drug class can unlock therapies for widespread cardiometabolic conditions. Michael Hamacher of KHAN said the company has "a unique opportunity to deliver disease-modifying medicines and reshape the standard of care."
Read more: EU-Startups
Image credit: NavyMedicine
